Shopping Cart
- Remove All
- Your shopping cart is currently empty
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $198 | In Stock | |
5 mg | $579 | In Stock | |
10 mg | $928 | In Stock | |
25 mg | $1,370 | In Stock | |
50 mg | $1,850 | In Stock | |
100 mg | $2,480 | In Stock |
Description | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer. |
In vitro | Leronlimab (1-140 mg/mL) binds to CCR5-positive cells up to 98% and (80-1750 μg/mL) inhibits calcium response induced by CCL5, CCL3, and CCL4 in MDA-MB-231 cells. Additionally, Leronlimab (175 and 350 mg/mL) blocks the invasion of MDA-MB-231 cells and (10 μg/mL; 72 hours) enhances the cytotoxicity of doxorubicin against these cells[1]. |
In vivo | Leronlimab (2 mg; intraperitoneal injection; twice a week) reduces lung metastasis in a mouse xenograft model[1]. |
Alias | PRO 140 |
Molecular Weight | 146.66 kDa |
Cas No. | 674782-26-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.